
Please try another search
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.
Name | Age | Since | Title |
---|---|---|---|
James F. Young | 68 | 2010 | Independent Chairman of the Board |
Richard Huntington Douglas | 70 | 2010 | Independent Director |
Rachel K. King | 64 | 2018 | Independent Director |
David M. Mott | 58 | 2020 | Independent Director |
John Charles Jacobs | 55 | 2023 | President, CEO & Director |
Margaret G. McGlynn | 64 | 2020 | Independent Director |
Gregg Huber Alton | 57 | 2020 | Independent Director |
Richard J. Rodgers | 56 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review